Evidence map›Paper›PMID 42634420›Full record

ArticleChemical biology & drug design2026

Tyrosinase Inhibitors With Enhanced Potency in Mammalian and Vertebrate Models, N-(2-Mercaptoethyl)benzamide Derivatives: Design, Synthesis, and Evaluation.

Hyunhee Ju, Minchang Kim, Hyunju Lee, Hee Jin Jung, Yeonsoo Jeong, Hyejin Kang, Hyeon Seo Park, Hae Young Chung, Hyung Ryong Moon

Abstract read
In one paragraph

Article in Chemical biology & drug design, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Hyunhee JuDepartment of Manufacturing Pharmacy, College of Pharmacy and Research Institute for Drug Development, Pusan National University, Busan, Republic of Korea.ORCID https://orcid.org/0009-0003-5779-1333
Minchang KimDepartment of Manufacturing Pharmacy, College of Pharmacy and Research Institute for Drug Development, Pusan National University, Busan, Republic of Korea.ORCID https://orcid.org/0009-0003-9981-6869
Hyunju LeeDepartment of Manufacturing Pharmacy, College of Pharmacy and Research Institute for Drug Development, Pusan National University, Busan, Republic of Korea.
Hee Jin JungDepartment of Manufacturing Pharmacy, College of Pharmacy and Research Institute for Drug Development, Pusan National University, Busan, Republic of Korea.ORCID https://orcid.org/0000-0001-7212-5572
Yeonsoo JeongDepartment of Manufacturing Pharmacy, College of Pharmacy and Research Institute for Drug Development, Pusan National University, Busan, Republic of Korea.ORCID https://orcid.org/0009-0001-4311-8805
Hyejin KangDepartment of Manufacturing Pharmacy, College of Pharmacy and Research Institute for Drug Development, Pusan National University, Busan, Republic of Korea.
Hyeon Seo ParkDepartment of Manufacturing Pharmacy, College of Pharmacy and Research Institute for Drug Development, Pusan National University, Busan, Republic of Korea.
Hae Young ChungDepartment of Pharmacy, College of Pharmacy, Pusan National University, Busan, Republic of Korea.ORCID https://orcid.org/0000-0002-3215-8828
Hyung Ryong MoonDepartment of Manufacturing Pharmacy, College of Pharmacy and Research Institute for Drug Development, Pusan National University, Busan, Republic of Korea.ORCID https://orcid.org/0000-0003-1119-7112

Funding

Pusan National University
6 · The paper itself

Abstract

Retaining structural features that allow 2-mercaptomethylbenzimidazole compounds to function as Cu(II) chelators, N-(2-mercaptoethyl)benzamide (NMEB) derivatives 1a-1m were designed, synthesized, and assessed for their potential as Cu(II) chelators. Derivative 1m inhibited mushroom tyrosinase (mTYR) activity twice as potently as kojic acid (KA) in the presence of l-DOPA. The mechanisms by which three derivatives, including 1m, inhibit mTYR were elucidated through kinetic studies. Interestingly, all NMEB derivatives suppressed melanogenesis more potently than KA in B16F10 cells, significantly reducing melanin production in a concentration-dependent manner. NMEB derivatives also inhibited cellular TYR activity in keeping with their melanogenesis inhibition, indicating B16F10 cellular TYR inhibition to be the primary mechanism. Moreover, among these derivatives, 1a inhibited zebrafish larval pigmentation hundreds of times more potently than KA. In mammalian cells and zebrafish larvae, NMEB derivatives showed even higher TYR-inhibitory or antimelanogenesis potency than mushrooms. Due to differences in the amino acid sequence and location of TYRs, NMEB derivatives appear to differ in their inhibition of TYR activity and melanin production in different species. This study points out limitations in the development of novel TYR inhibitors based on mTYR inhibition results and provides fundamental data supporting their development as novel skin-lightening agents.

Indexed as

BenzamidesDrug DesignEnzyme InhibitorsMonophenol MonooxygenaseAgaricalesAnimalsCell Line, TumorHumansMelaninsMelanogenesisMicePyronesStructure-Activity RelationshipZebrafishBenzamidesEnzyme Inhibitorskojic acidMelaninsMonophenol MonooxygenasePyroneskojic acidmelaninN‐(2‐mercaptoethyl)benzamidepigmentationtyrosinase

Identifiers

PMID42634420
PMCPMC13501074

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.